Time for Pfizer to buy Leronlimab for NASH.
Post# of 148110
“The Big Pharma just dropped the ketohexokinase inhibitor PF-06835919 after a mid-stage trial a year ago, and had previously halted PF-05221304 and a DGAT2 inhibitor for the liver condition.”
Remember they brought one to the NASH conference where we announced 350 results, then they withdrew it, surprise, surprise.
Time big boy to get something that works, duh.